scholarly journals Subsyndromal and syndromal depressive symptoms among older adults with schizophrenia spectrum disorder: Prevalence and associated factors in a multicenter study

2019 ◽  
Vol 251 ◽  
pp. 60-70 ◽  
Author(s):  
Nicolas Hoertel ◽  
Claire Jaffré ◽  
Rachel Pascal de Raykeer ◽  
Kibby McMahon ◽  
Sarah Barrière ◽  
...  
Keyword(s):  
Older Adults ◽  
Depressive Symptoms ◽  
Multicenter Study ◽  
Associated Factors ◽  
Spectrum Disorder ◽  
Schizophrenia Spectrum Disorder ◽  
Schizophrenia Spectrum

What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?

2015 ◽  
Vol 30 (1) ◽  
pp. 43-50 ◽  
Author(s):  
R. Schennach ◽  
M. Riedel ◽  
M. Obermeier ◽  
F. Seemüller ◽  
M. Jäger ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Depression Scale ◽  
Spectrum Disorder ◽  
Research Network ◽  
Underlying Structure ◽  
Positive Symptoms ◽  
Naturalistic Study ◽  
Schizophrenia Spectrum Disorder ◽  
Schizophrenia Spectrum ◽  
Study Results

AbstractBackground:Aim was to examine depressive symptoms in acutely ill schizophrenia patients on a single symptom basis and to evaluate their relationship with positive, negative and general psychopathological symptoms.Methods:Two hundred and seventy-eight patients suffering from a schizophrenia spectrum disorder were analysed within a naturalistic study by the German Research Network on Schizophrenia. Using the Calgary Depression Scale for Schizophrenia (CDSS) depressive symptoms were examined and the Positive and Negative Syndrome Scale (PANSS) was applied to assess positive, negative and general symptoms. Correlation and factor analyses were calculated to detect the underlying structure and relationship of the patient’s symptoms.Results:The most prevalent depressive symptoms identified were depressed mood (80%), observed depression (62%) and hopelessness (54%). Thirty-nine percent of the patients suffered from depressive symptoms when applying the recommended cut-off of a CDSS total score of > 6 points at admission. Negligible correlations were found between depressive and positive symptoms as well as most PANSS negative and global symptoms despite items on depression, guilt and social withdrawal. The factor analysis revealed that the factor loading with the PANSS negative items accounted for most of the data variance followed by a factor with positive symptoms and three depression-associated factors.Limitations:The naturalistic study design does not allow a sufficient control of study results for the effect of different pharmacological treatments possibly influencing the appearance of depressive symptoms.Conclusion:Results suggest that depressive symptoms measured with the CDSS are a discrete symptom domain with only partial overlap with positive or negative symptoms.

Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How?

2017 ◽  
Vol 50 (04) ◽  
pp. 136-144 ◽  
Author(s):  
Rebecca Schennach ◽  
Michael Obermeier ◽  
Florian Seemüller ◽  
Markus Jäger ◽  
Max Schmauss ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Side Effects ◽  
Acute Treatment ◽  
Negative Symptoms ◽  
Well Being ◽  
Spectrum Disorder ◽  
Positive Symptoms ◽  
Subjective Well Being ◽  
Schizophrenia Spectrum Disorder ◽  
Schizophrenia Spectrum

Abstract The aim of this study was to evaluate antidepressant add-on treatment within the acute treatment of schizophrenia spectrum disorder patients. Antidepressant add-on was evaluated in 365 patients within a naturalistic multicenter study. Patients with/without antidepressant add-on were compared regarding clinical and treatment-related variables, response and remission, and remission of depressive and negative symptoms. The efficacy of antidepressant add-on treatment was furthermore analyzed applying marginal structure models. Twenty-three percent of the patients received antidepressant add-on for a mean duration of 50.28 (33.42) days. Patients with the diagnosis of a schizoaffective disorder, multiple illness episodes, and a longer duration of their illness as well as those with significantly fewer baseline positive symptoms, more negative and depressive symptoms, more side effects, and less subjective well-being were augmented with antidepressants. At discharge no significant effect of antidepressant add-on treatment was observed in terms of a 25% improvement (p=0.2623), a 50% improvement (p=0.3946), remission (p=0.0552), or remission of depressive (p=0.6336) and negative symptoms (p=0.8756). Also, when analyzing marginal structure models considering the diagnostic subgroups, no significant effect was found. Add-on with antidepressants is common. A final recommendation in terms of this strategy’s efficacy cannot be given.

Sign in / Sign up

Export Citation Format

Share Document